Approval · Notice of Compliance 28508 · 2022
WEGOVY: Notice of Compliance 28508
Issued June 30, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28508
- Date
- June 30, 2022
- Company
- Novo Nordisk Canada IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New presentation
Products in this notice
Medicinal ingredients
- SEMAGLUTIDE 0.68 MG per ML
- SEMAGLUTIDE 1.34 MG per ML
- SEMAGLUTIDE 2.27 MG per ML
- SEMAGLUTIDE 3.2 MG per ML